These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). Fairman J; Agarwal P; Barbanel S; Behrens C; Berges A; Burky J; Davey P; Fernsten P; Grainger C; Guo S; Iki S; Iverson M; Kane M; Kapoor N; Marcq O; Migone TS; Sauer P; Wassil J Vaccine; 2021 May; 39(23):3197-3206. PubMed ID: 33965258 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. Zangwill KM; Greenberg DP; Chiu CY; Mendelman P; Wong VK; Chang SJ; Partridge S; Ward JI Vaccine; 2003 May; 21(17-18):1894-900. PubMed ID: 12706674 [TBL] [Abstract][Full Text] [Related]
8. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594 [TBL] [Abstract][Full Text] [Related]
9. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583 [TBL] [Abstract][Full Text] [Related]
10. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Gruber WC; Scott DA; Emini EA Ann N Y Acad Sci; 2012 Aug; 1263():15-26. PubMed ID: 22830997 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA; Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707 [TBL] [Abstract][Full Text] [Related]
12. Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges. Jain SS; Singh VK; Kante RK; Jana SK; Patil RH Biologicals; 2024 Aug; 87():101784. PubMed ID: 39053122 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides. Tan CY; Immermann FW; Sebastian S; Pride MW; Pavliakova D; Belanger KA; Watson W; Scott DA; Sidhu M; Jansen KU; Giardina PC mSphere; 2018 Aug; 3(4):. PubMed ID: 30089644 [TBL] [Abstract][Full Text] [Related]
14. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). Nuorti JP; Whitney CG; MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868 [TBL] [Abstract][Full Text] [Related]
15. Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines. Smith WJ; Thompson R; Egan PM; Zhang Y; Indrawati L; Skinner JM; Blue JT; Winters MA Vaccine; 2023 Aug; 41(35):5113-5125. PubMed ID: 37321893 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial. Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525 [TBL] [Abstract][Full Text] [Related]